In contrast, low total macrophage number defined by CD68 expression is an independent factor for better DFS in pN2 stage IIIA NSCLC patients receiving neoadjuvant chemotherapy (NAC) (cisplatin/docetaxel) from the Chinese cohort (187). This evidence concerns the gene CD68 and non-small cell lung carcinoma.